Levi & Korsinsky has opened an investigation into Corcept Therapeutics following reports that the company manipulated its patent process over its flagship product Korlym, potentially misleading investors and stifling Teva's generic competition. This action has triggered a notable drop in the company's stock price.

Pomerantz LLP has initiated an investigation into allegations of securities fraud and potential manipulation of patent processes at Corcept Therapeutics, an event that has also resulted in a significant stock price drop. The inquiry focuses on claims of unlawful practices by certain company leadership, raising concerns about corporate accountability and fair competition.

Aetna Inc. and other major health insurers have filed a lawsuit against Corcept Therapeutics, alleging that the company engaged in unethical practices including bribing doctors, controlling drug distribution, and manipulating the patent system to stifle generic competition for its drug Korlym, ultimately increasing costs for patients.

Corcept Therapeutics is under investigation by the DOJ for alleged off‐label marketing of its drug Korlym. The company is accused of lowering diagnostic criteria and aggressively promoting the drug for unapproved indications, raising serious patient safety and ethical concerns.